TADA3L, also known as Transcriptional Adaptor 3-Like, is a protein involved in transcriptional regulation and chromatin remodeling. As direct activators of TADA3L are not well-established, the focus shifts to chemicals that can indirectly influence its activity through the modulation of related pathways or cellular processes. The primary class of compounds listed here includes histone deacetylase (HDAC) inhibitors. These compounds, such as Trichostatin A, SAHA (Vorinostat), RGFP966, M344, Entinostat, Scriptaid, Panobinostat, Sodium Butyrate, Valproic Acid, Romidepsin, and Belinostat, function by inhibiting the activity of histone deacetylases. Histone deacetylases are enzymes that remove acetyl groups from histone proteins, leading to chromatin condensation and reduced transcriptional activity. By inhibiting these enzymes, HDAC inhibitors cause an increase in histone acetylation, leading to a more relaxed chromatin structure and enhanced transcription of various genes. This change in the transcriptional landscape can indirectly affect proteins like TADA3L, which are involved in transcriptional regulation and chromatin organization.
Another class of compounds is DNA methyltransferase inhibitors, represented by 5-Azacytidine. This compound inhibits DNA methyltransferases, enzymes responsible for adding methyl groups to DNA, which usually results in gene silencing. By inhibiting these enzymes, 5-Azacytidine can lead to demethylation of DNA and subsequent activation of previously silenced genes. This alteration in gene expression can indirectly impact the function and regulation of proteins like TADA3L.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
A DNA methyltransferase inhibitor, it can lead to changes in gene expression that might indirectly affect TADA3L activity. | ||||||
RGFP966 | 1357389-11-7 | sc-507300 | 5 mg | $115.00 | ||
Selective histone deacetylase 3 inhibitor, potentially altering the expression of genes in the TADA3L network. | ||||||
M 344 | 251456-60-7 | sc-203124 sc-203124A | 1 mg 5 mg | $109.00 $322.00 | 8 | |
A potent HDAC inhibitor, which could indirectly influence TADA3L through epigenetic modifications. | ||||||
MS-275 | 209783-80-2 | sc-279455 sc-279455A sc-279455B | 1 mg 5 mg 25 mg | $24.00 $90.00 $212.00 | 24 | |
An HDAC inhibitor that can modify gene expression, possibly affecting TADA3L-related pathways. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $31.00 $47.00 $84.00 $222.00 | 19 | |
Histone deacetylase inhibitor that affects chromatin remodeling and gene expression, potentially influencing TADA3L activity. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $87.00 | 9 | |
An HDAC inhibitor that can modulate gene expression and potentially affect TADA3L-related pathways. | ||||||
Romidepsin | 128517-07-7 | sc-364603 sc-364603A | 1 mg 5 mg | $218.00 $634.00 | 1 | |
A cyclic peptide HDAC inhibitor, which could have an indirect effect on TADA3L through changes in gene expression. | ||||||